CBD Europe💯💚


Aurora Cannabis Completes Hempco Food and Fibre Acquisition

Hempco provides Aurora with access to low-cost, high-volume raw hemp material

Aurora identified the potential of hemp-derived CBD early on, completing its first investment in Hempco in 2017, and has subsequently expanded its hemp-based infrastructure through targeted acquisitions and strategic partnerships.

 Aurora Hemp: an integrated operating unit executing the Company’s Global Hemp Strategy.

for the extraction of primarily cannabidiol (“CBD”) and other cannabinoids

With expertise across genetics, extraction, product development, brands and distribution, Aurora Hemp is an end-to-end offering across the entire hemp value chain:


Hempco, a trusted and respected pioneer, innovator and provider of quality, hemp-based foods, hemp fiber, and hemp nutraceuticals. Brands include PLANET HEMP™ and PRAISE, hemp-based foods and nutritional supplements for people and animals. Hempco is nearing completion of a new, state-of-the-art Nisku facility, a 56,000 square foot, 2.9 million kg per year hemp processing facility.

Agropro, Europe’s largest producer of organic hemp and hemp-based food products has extensive experience in sowing seeds, growing, machine harvesting, drying and cleaning biomass in preparation for food processing or extraction into CBD.

Borela, a processor and distributor across the European Union of organic hulled hemp seeds, hemp seed protein, hemp flour, and hemp seed oil.

ICC Labs, a Latin American based producer and distributor of cannabinoid products for recreational and medicinal use with operations in Uruguay and Colombia. ICC has access to high CBD hemp genetics available for export to international jurisdictions.

Anandia Labs, the industry leader in science, genetics, and independent cannabis product testing to provide rigorous product testing and quality assurance, ensuring safe and efficacious consumer products.

Radient Technologies, a provider of industrial-scale manufacturing solutions with a technology platform designed for high extraction and high-volume throughput of cannabinoids available in the plant biomass.

UFC Clinical Research and Product Development, through this partnership Aurora and UFC will research and examine the use of hemp-derived CBD as an effective treatment for pain, inflammation, wound-healing, and recovery on MMA athletes. Research data will then be used to drive the development of a portfolio of science-backed, high-quality, hemp-derived CBD topical treatments, under the new high-performance sports brand ROAR Sports.

“Aurora is defining the future of cannabis and hemp, globally,” said Terry Booth, CEO of Aurora. “Through the addition of Hempco, we have assembled a world-class portfolio of high-quality hemp assets that together form the basis of a strong new operating division that will develop CBD-from-hemp around the world. Aurora Hemp brings together the cultivars, strategic partners, brands, and distribution networks to service medical, consumer, and wellness markets and further advances Aurora’s entry into the US hemp food and hemp-derived CBD markets.”


Luxembourg to be first European country to legalise cannabis💯

Luxembourg has called on its EU neighbours to relax their drug laws as its health minister confirmed plans to become the first European country to legalise cannabis production and consumption.

Luxembourg will follow Canada in legalising the possession of 30 grams of cannabis.

“This drug policy we had over the last 50 years did not work,” Etienne Schneider told Politico. “Forbidding everything made it just more interesting to young people … I’m hoping all of us will get a more open-minded attitude toward drugs.”

Tax revenues will be reinvested in drug education and addiction treatment programmes

Draft legislation is expected to be unveiled later this year providing further detail on the types of cannabis that will be on sale and the level of tax that will be imposed.

Residents over the age of 18 are expected to be able to buy the drug for recreational use legally within two years. The state will regulate production and distribution through a cannabis agency.

Schneider said the legislation was likely to include a ban on non-residents buying cannabis in order to dissuade drug-tourism. Home-growing is also likely to be prohibited.

Aurora Cannabis Update Fourth Quarter

Aurora the Canadian company defining the future of cannabis worldwide, today provided a corporate update on selected financial metrics for the fourth quarter of the Company’s Fiscal 2019 (“Q4 2019”) period ended June 30, 2019.

Based on a preliminary (unaudited) review, the Company anticipates net revenues for the quarter ended June 30, 2019of between $100 million and $107 million (net of excise taxes), compared to $19.1 million in the period ended June 30, 2018, and compared to $65.1 million for the previous quarter ended March 31, 2019.  


Fiscal Q4 2019 net cannabis revenue is expected to be between $90 million and $95 million, with growth anticipated across all key business segments including medical, both Canadian and international, and consumer markets.  The Company anticipates total net revenues for the fiscal year ended June 30, 2019 to be between $249 million – $256 million.


The Company expects to report that production available for sale for Q4 2019 will be at the upper end of the range between 25,000 kg and 30,000 kg, ahead of previous guidance of 25,000 kgs.

Aurora’s management team and Board of Directors continue to drive a culture rooted in quality, transparency, and regulatory compliance. Aurora has grown both organically and through acquisitions of companies with shared visions, and today this culture is ingrained in Aurora’s over 2,500 employees across the globe.

“Our Q4 2019 guidance highlights Aurora’s continued leadership,” said Terry Booth, CEO of Aurora. “We set out to be best-in-class cultivators, and through carefully evaluated acquisitions, that vision continues to drive exceptional results today. We are the leader in cultivation capacity, production available for sale and revenues for cannabis in the Canadian medical and consumer markets.

We continue to lead the build out of European and other international medical cannabis markets. Our success to date comes from a focus on quality, regulatory compliance, appropriate Board of Directors oversight, and delivering a profitable, low risk and sustainable business for our shareholders.”


Choom Acquires 7 Additional Cannabis Retail Locations in BC and Alberta

Choom™ (CSE: CHOO; OTCQB: CHOOF), an emerging adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that it has signed a definitive agreement to acquire The Green Room, a popular cannabis retail store chain which has operated since 2016.

The agreement involves the purchase of location assets from The Green Room which includes three (3) locations in British Columbia and four (4) locations in Alberta. The Green Room locations in Alberta and British Columbia feature several premiere locations for cannabis retail stores with multiple years of successful operation.

“Green Room was a highly successful operator that originally opened in Vancouver as a compassion club offering medicinal cannabis to their patients.  Choom looks to build on the good reputation they have in the communities they served and open legal cannabis retail stores in their successful locations.” states Chris Bogart, President and CEO of Choom “Our priority for these locations are to bring our unique Choom experience that encourages sharing education with consumers about the safe and responsible use of cannabis.”

The two locations in Vancouver are expecting to receive development permits to operate legal cannabis retail stores. The location in Squamish has municipal approval and is awaiting approval from the Liquor & Cannabis Regulation Branch of British Columbia (“LCRB”). 


 Three of the four acquired locations in Alberta have received development permits from the applicable municipalities to operate cannabis retail stores.  Choom will submit its applications for cannabis retail store licenses to the Alberta Gaming, Liquor & Cannabis Commission (“AGLC”) at its earliest convenience.

Building Europe’s Medical Cannabis Industry💯

The leaders of the medical cannabis industry in the heart of the city of London

On the 24th-25th of June 2019

the Southbank CentrE

#CannabisEuropa @southbankcentre

This two-day event will explore the latest developments in the UK market and the professionalisation of the industry across the European continent


Aurora Cannabis Inc (TSE:ACB) on UK becoming Medical Cannabis Global Leader

Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB)(FRA:21P) CCO Cam Battley visits James at the Cannabis Europa Conference in London, UK. Cam Battley was a guest speaker and discusses the potential for the UK to be a leader in medical cannabis on a global basis. While regulations at the moment make it a challenging process to provide medical patients with accessible cannabis products, Battley knows that Aurora can overcome those hurdles.

Andrew Neil chairing latest session #CannabisEuropa

BBC’s Andrew Neil hosts a panel with Conservative MP Crispin Blunt, Lib Dem Norman Lamb and PCC for Avon and Somerset Sue Mountstevens… Lamb holding Mountstevens to task

Good to see norman lamb and Crispin Blunt making a strong case for legalising and regulating recreational cannabis for adults.

“There is a price to be paid for being cautious” says normanlamb as to whether the UK can wait years to see the evidence from Canada #cannabiseuropa #CannabisEuropa

Lots of great podcasts being recorded here today at CannabisEuropa, including the VoltefaceHub Podcast, TheCannabisCon2 and ValensGroWorks

Prime Minister of Malta Joseph Muscat speaks at CannabisEuropa about how legalising & regulating research & medicinalcannabis production has brought investment & jobs to the country.

Lesotho was first African country to legalise cultivation and export of medicinalcannabis. Prime Minister of the Kingdom of Lesotho, Monyane Moleleki, speaks at CannabisEuropa about how medicinal cannabis has been key to Lesotho’s growth & poverty eradication strategy.


deepak anand discussing CBD legalization, and new regulations rolling out on MidasLetter

“The Responsible Face of the Industry” panel at cannabiseuropa

MP Connie cowan now discussing the ‘ignorance’ of the Home Office for failing to open dialogues regarding the access of cannabis for patients.

Crispin Blunt currently in the Valens PodBooth at Cannabis Europa talking about Britain’s political strides towards more progressive cannabis policy.

“Social justice is core to this community, and it’s a community not just an industry”

Jonathan Zaid of Aurora

With over 80 speakers across 18 talks, Cannabis Europa London has something for everybody.

Our panelists will be discussing the most pressing issues facing the European industry today, analysing the developments of the last 12 months and looking at how medical cannabis has permeated the mainstream.

With a line up of prominent politicians and policymakers, inspirational business leaders and healthcare professionals, unwavering advocates and ingenious entrepreneurs, we are shaping the debate across the continent.

Aurora Cannabis Extends Exclusive Supply Relationship with Luxembourg

Aurora Deutschland has been selected by the Luxembourg Health Ministry as the exclusive supplier in a public bid to supply the second delivery of medical cannabis to Luxembourg.


Under the terms of the bid, the medical cannabis produced will be sold to Luxembourg’s Division de la Pharmacie et des Medicaments, representing the second time the Company has received an order directly from the Luxembourg government. While the initial bid quantities are small, the award confirms Aurora’s position as a trusted and preferred supplier to international jurisdictions and reflects the Company’s ability to work with local governments and regulators in complex, restricted markets.

“We are proud to continue serving as the exclusive supplier of medical cannabis to the Luxembourg Health Ministry,” said Neil Belot, Chief Global Business Development Officer. “Adding to the many achievements of our European team, which also includes our recent selection as one of only three companies to establish domestic production in Germany, our expanded supply agreement with Luxembourg reinforces Aurora’s ability to act as a trusted partner that can readily meet the complex needs of diverse international markets.”

Maximilian Weinberg, Associate Director of Aurora’s EU Business Development, added, “As the established market leader across Europe, Aurora is exceptionally well positioned to leverage our significant early mover advantage to accommodate the growth of new medical cannabis markets as opportunities arise. We’re proud of our teams’ achievements to date and look forward to supplying patients in Luxembourg with improved access to high quality medical cannabis.”

About AuroraMJ

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 24 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora’s facilities is built to meet EU GMP standards. EU GMP certification has been granted to Aurora’s first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 16 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, and Whistler – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including:

Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), and EnWave Corporation (TSXV: ENW).

Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index.


Aphria Completes German Tender Process and Receives Fifth Culitvation License in Germany

Aphria Inc, today announced that its German subsidiary Aphria Deutschland GmbH (“Aphria Germany“) had been awarded a fifth lot for the cultivation of medical cannabis in Germany as part of the Company’s previously awarded license from the German Federal Institute for Drugs and Medical Devices (“BfArM“).

The additional lot was provisionally awarded to Aphria Germany in April and was secured following a review by a German court, which affirmed the original decision by the BfArM.

With this decision, Aphria Germany won the maximum output from the German tender process – a total of five lots – and stands as the only licensed producer in Germany with the permission to grow all three strains of medical cannabis approved by the BfArM.

“We are thrilled about our successful conclusion to the German tender process, which has awarded Aphria with the most comprehensive license in the country,” said Hendrik Knopp, Managing Director of Aphria Germany.

Aphria Germany is building its over 8,000 square meter indoor growing facility in Neumünster and is completing work on a state-of-the-art GMP-certified cannabis vault in Bad Bramstedt for the import of cannabis flowers and oil from Canada, Australia and Denmark. Aphria Germany also holds a 25.1% interest in Berlin-based Schöneberg Hospital, which provides access to both doctors and patients for education on the benefits of medical cannabinoids.

The company also recently introduced CannRelief, a CBD-based nutraceutical and cosmetics product line for the German market, produced in the EU and distributed by CC Pharma, a subsidiary of Aphria with access to more than 13,000 pharmacies throughout Germany.

Canopy Growth Acquires Germany’s C3 Cannabinoid Compound Company

The all cash-acquisition for €225.9 million

“What this boils down to is greater choice,” said Bruce Linton, Chairman & Co-CEO, Canopy Growth. “This acquisition will allow us to offer more options to physicians across Europe, accelerate our commercial sales and increase our economic footprint on the continent, and drive forward new innovations. Our goal is to build on C3‘s extraordinary reputation and decades of success as we move to an innovative continuum of medical cannabis therapies that will enable physicians globally to better treat their patients.”

Three companies were chosen to cultivate medical marijuana in Germany.

This is a watershed moment for  operations in Germany


We are very proud to have been selected as one of only three companies by the German government, which is a great achievement by our team. Having the highest rated concept is a strong validation of the Aurora Standard cultivation philosophy, as well as of our track record in the delivery of safe and high-quality medical cannabis products to the German system


Aphria Awarded Provisional Approval in Germany for Cannabis Cultivation License


Aphria is proud to have been selected as a successful applicant in the German tender process, a testament to our high production quality standards,” said Hendrik Knopp, Managing Director of Aphria Germany. “The decision from BfArM is a validation of our strategic approach to supporting the German medical cannabis market, including with high-quality, domestic production to secure vital supply for patients. We are very pleased with our continued business momentum in Germany.”

Wayland Selected as One of Three Groups for Cannabis Production Licenses in Germany


From the beginning, the market opportunity for medical cannabis in Germany has been a key part of Wayland’s global growth strategy. The Company has always prioritized Germany as one of the most exciting medical cannabis markets in the world given its progressive regulations, rapidly expanding the patient population, and insurance coverage for over sixty percent (60%) of prescriptions.

European Cannabis Industry Update Report

While the American cannabis industry deals with both unparalleled opportunity and new risks, Europe is setting itself up for a spring that is going to be verdant.

The ongoing drumbeat for reform in countries across the continent is bringing both money and high-grade medical product into the market. Even if volume is still really at a trickle, it will rapidly widen to a steady stream. It is also very clear that the next two to three quarters are going to deliver news that the cannabiz has arrived, and with authority.

The following is an overview of what is happening, where, and with an eye to informing foreign investors, in particular, about new opportunities in an awakening market.


Without a doubt, the country is priming itself for a medical market that is going to be large and partially government supported, driving regulation of medical use across the continent. On top of that, the idea of selling 28 grams (1 oz) of product to end consumers who only pay about $12 for their medication has gotten the attention of global producers. Opportunities here for those who did not submit a bid for federal cultivation (see the big Canadian LPs) are still unfolding.

german flag

However here is what is now on the table: an import market that cannot get enough cheap, GMP certified product. Producers from Australia to Uruguay are now actively hunting for a way in, even if cutting a supply deal for the next 18 – 24 months as the German green machine starts to kick into production-ready status. What a bad time for Israel to be so publicly out of the ex-im biz! In fact, Israeli entrepreneurs are scouring the country for opportunities into the market another way (and there are a few efforts afoot in a sleeping giant of a market waking up from a long snooze to find they cannot get enough product). Right now, however, the legal market is absolutely dominated by Canopy, Aurora, Aphria and Tilray along with Dutch Bedrocan.

The German parliament is clearly also going to do something about another piece of reform which will also drive market expansion – starting with announcement of additional cultivation possibilities (potentially this time even open to German firms). On Friday, the day after the British parliament wrangled over the same thing, the German Bundestag debated decriminalization along with a few other hot button topics (like abortion). With only the AfD (right wing) still in the “lock ‘em up camp,” and even the head of the police calling for reform, it is clear that decriminalization is on the legislative agenda this year.

Spain, Italy, Switzerland, Portugal, Denmark & Holland

While it may seem presumptuous to lump all these very different countries under one label, the reality is that the level of reform is generally in a similar state (transition to medical), and that drives potential political and market risk as well as evaluation of investment decisions.

aurora logoIn Spain, federal reform has not come yet, but medical deals involving pharmaceutical companies (both exclusively cannabinoid focussed and otherwise) are afoot. Plus of course there is Barcelona (the Colorado of the country in many ways).

Italy, Portugal and Denmark are all the battlegrounds for the big Canadian (and German) companies now set on having a country-by-country footprint in opening markets across the EU (see Canopy, Aurora, Aphria and their German counterparts of Spektrum Cannabis, Pedianos and Nuuvera). Licensing is political, happening at a high level, and only for those with the bank to back deals that come with high capex attached. That said, there are lucrative opportunities for those with local contacts and liquidity.Nuuvera logo

Holland is another animal altogether, but for the most part everyone is so confused about the state of reform domestically that the only people really in position to take advantage of it are the Dutch, at least for now. That said, Dutch-based plays (in part financed by Canadian backing) for other Euro markets are absolutely underway. Who else has so much experience here, let’s be honest? Regardless, investments in these canna markets, particularly for the Euro-focussed but North American investor, for now, will tend to be through public stock acquisitions of Canadian parents or direct investments in Dutch companies (see Bedrocan, but they are not the only game in town).

Switzerland, for the most part, is setting its own pace, but reform here means the CBD market, including for medical grade imports, is a place for the savvy medical investor to look for cultivation and ex-im opportunities. Including in the home-grown, Swiss pharma space.


The recent pronouncement of government officials that Greece was opening its doors to investment and a medical cannabis business means that there will be a federally legal, EU country that is promoting both investment and tourism opportunities just for domestic consumption, let alone export. Scouts from all the major canna companies are combing both the Greek mainland and its islands.


If there was ever such a thing as a “virgin” cannabis market, Poland might well qualify. For those distributors with cheap product that has not (yet) found a home, the country is poised to start to announce (at least) distribution deals to pharmacies with producers now establishing themselves in other markets. Medical legislation has just changed, in other words, but nothing else is in place. And with Polish patients now having, literally, to scour the continent for a product not to mention foot the bill for the travel costs to get it, the next obvious step is a national pharmacy chain distribution deal or two with producers from all over the world now looking for Euro market entry possibilities. Domestic production is some time off.

reform in countries across the continent is bringing both money and high-grade medical product into the market

If there were such a thing as the “Berlin” of the cannabis market in Europe (namely sexy but poor), it is probably going to be here. Cheap production markets and opening opportunities for export across the EU for high quality, low cost cannabis are not going unnoticed. Look for interesting plays and opportunities across the region. Scouts from the big international canna companies already are.

The UK

Britain comes last because of the political uncertainty in general, surrounding the island. However, last week Parliament appeared on the verge of being embarrassed into acting on at least medical reform. There will be a market here and of course, there is already one globally known cannabis company with a 19-year track record and a monopoly license on canna-medical research and production (GW Pharmaceuticals) that calls the British Isles home. This will be a no-brainer, particularly for foreign English-speaking investors still leery of continental Europe. However it will also be highly politically connected. Expect to see a few quick arranged marriages between such landed gentry and foreign capital – potentially even this year.

cbd #cbduk #cannabis #medicalcannabis #hemp

Cbd Coffee Shop👍💯

CBD coffee has arrived

Starbuds cannabis coffee shop opens its doors in the UK

A cannabis coffee shop of the future

Sheffield’s very first cannabis themed coffee shop has opened and yes, it is legal!

A coffee shop with a difference has officially opened its doors in Sheffield – selling cuppas laced with cannabis.

Starbuds Coffee in Chesterfield Road has already been up and running for a few months but owner Imogen Pollard has now officially launched her new business – and spoken out to assure customers that the shop is totally legal.

A cannabis coffee shop has opened its doors to customers in the UK offering people the opportunity to try their CBD infused products.

Starbuds cannabis coffee shop in Sheffield recently opened its doors to offer coffees, cakes and other foods infused with CBD in the wake of the new CBD health trend.

www.cbdcafes.co.uk #cbdcafes www.thecbdcafe.co.uk #thecbdcafe

“The first thing people ask when they order a coffee is ‘will it get me high?’ Absolutely not because if it did, we wouldn’t be allowed to be in business.

“We want to get the message out there that we’re offering something a bit different, but its not about getting stoned or high or anything like that.

The cafe, at 111 Chesterfield Road, is open from 9am to 5pm, seven days a week.

“We are offering coffees and cakes that can help people with ailments and medical conditions. That’s what the shop is all about.”

Starbuds Cannabis Coffee Shop
111 Chesterfield Road
S8 0RN

Medical CBD products are available


Starbuds cannabis coffee shop is selling a number of CBD products including paste, topicals, CDB oil, boiled sweets infused with oils, and will be infusing CBD into food, such as dressings and salsa, in the future. The products are part of their own CBD range named ‘How’.

Alongside coffees and snacks, the shop sells eight different flavours of medical CBD flower, the non-psychoactive flower that can be used for medical purposes, including

tropicana, blackberry, blue dragon, cheese, strawberry, amnesia, grape and white widow – ranging from 10.5% to 14.9% CBD content.

Imogen, 34, was moved to start up Starbuds (and more about that name later!) after seeing CBD cafes springing up in other parts of the country.

It’s not the psychoactive cannabinoid that gets you high called THC.

Instead, its a product that many users believe to have medicinal properties which help with pain relief for a number of conditions including cancer, epilepsy and Alzheimer’s.

It also helps people with stress and anxiety relax.

The shop conjures up the air of a traditional Amsterdam coffee shop – the Dutch city where of course, its legal to smoke cannabis in public.

But despite depictions of cannabis leaves across the premises, that’s where the similarity ends.

“We wanted to emulate that vibe,” she adds. “But at the end of the day, we’re just a coffee shop offering drinks with CBD in them.”

However, the shop is not without some controversy – American coffee giant Starbucks has already ordered Imogen to change the name of the cafe.

“It was a cheeky nod to Starbucks,” she added, “but they said the name and logo was too similar to theirs and want us to change it.

“We don’t really have a choice because they are so huge, so we’ll have to think of something new. It has given people a laugh when they have seen the name driving past though.”


She plans to extend the range of CBD products on offer over the coming months as well as applying for an alcohol licence.

Added Imogen: “If it was illegal, we wouldn’t be allow to sell it. Lots of our customers say it helps them relax, it takes away pain and helps ease them through the day.

“It help shifts the brain fuzz that we all get in our daily lives and takes the edge off things for a lot of people.”

Personal benefits from CBD

Mr Chu said: “Me and one of the partners were going down the health and wellbeing route and decided to go with a CBD cannabis coffee shop. At the time I was under enormous amounts of stress and developed a Tourette’s-like tick that I could not get rid of.

“I started taking prescriptions to counteract it, but nothing worked, so I tried CBD oil. In ten or twenty minutes the twitches had gone, and they never came back. After that I carried on taking it and realised my mental health had improved and my aches and pains had gone, along with lots of other benefits.

“I started doing more research and met a lot of people. I heard so many stories from people about how cannabis oil has helped them. People have gone from taking ten or fifteen medications a day down to one – just a couple of drips of oil. It is amazing.

“There is a lot of confusion about the product – the first thing people think is ‘am I going to get high?’ but it is nothing like that. The CBD products are non-psychoactive so they cannot possibly have a psychoactive effect on anyone.”

A cannabis coffee shop of the future

Mr Chu continued: “We opened the doors and saw people trickle in – now we have built up relationships and have many customers from the community who meet up here regularly and love the chilled atmosphere.

“The medical cannabis is a different product – this is a supplement that can be incorporated with other products. We hope people’s attitudes towards cannabis will change and we feel a lot more research needs to be done – this product needs to be in supermarkets.

“People have been on medication for years that has not helped them – one person had Lupus and has never found any relief in prescription creams. After buying 800 mg oil that is used directly on the skin the lupus has cleared up for them and they swear by it.

“I hope in the next five years we will be at the place Canada and America are now and coffee shops like this will hopefully become more normalised.”

CBD oil on BBC

cannabis is popular for calming anxiety

Natalie, who has bought a bottle of Cannabidiol (CBD) oil online, has a few questions she wants answering before she decides whether to take it.


On this journey Natalie meets a hemp farmer, a scientist and tests the product at a laboratory.

CBD products, which are made from a cannabis extract, are very popular but currently there is no specific regulation about their production.

CBD cafe selling drinks infused with cannabis

Bristol’s most recent addition to the city’s food and drink scene.

But this café is slightly different from the rest in that it has food and drinks on the menu that have been infused with cannabis.

Mary Jane’s, a name commonly used as a slang term for marijuana

And the slightly different offering is proving popular with Bristolians, with queues reaching to the door of customers wanting to try the new place.

At Mary Jane’s customers have the option of ordering a selection of food and drinks, including coffees, smoothies and milkshakes, containing CBD if they wish.

To accompany the range of coffees and other hot drinks on offer, Mary-Jane’s will be serving up a range of locally-made cakes and treats with a focus on catering for vegans, people with other dietary restrictions and the health-conscious.

Mary Jane’s will be Bristol’s first CBD coffee shop

Mary-Jayne’s opens to the public this Friday (May 31).


A café which will have hot drinks infused with cannabis on the menu is opening in Bristol this week.

“CBD infused with a Mary-Jane’s coffee it tastes amazing.

Mary Jane’s founder Jon Antoniou said: “Having tried various CBD products on the market I felt that there must be a better way to take it daily than on its own.

“Bristol is a real hub for healthy living and we want our products to reflect that so whether you’re gluten, lactose or nut intolerant or just believe that veganism isn’t just for January, we have options for you.”

Crussh has become the first UK grab-and-go chain to introduce cannabidiol products to its coffee offering after launching CBD oil boosters today.👍

Crussh launched its first iteration of the brand at City, University of London, last month after signing a franchise partnership with the foodservice provider in 2018.


CBD oil will be available across the brand’s 35 sites in the capital, but will not yet be available through its foodservice partner, Sodexo.

+ CBD – It’s the latest buzz word in the world of coffee. You can now add CBD oil to any coffee for £1.50. And relax… 

CBD coffee has arrived

The oil is offered as a £1.50 supplement by the health-food concept. It is made from naturally occurring compounds found in hemp and does not contain the psychoactive element – THC – contained in cannabis.

Proponents say CBD can help diminish mild anxiety as well as symptoms of epilepsy. Bars, restaurants and cafés across London, Manchester and Bristol have begun offering the substance in different foods and drinks, including truffles, cocktails and frozen yogurt.

Well CBD is short for cannabidiol, it is a naturally occurring chemical compound found in the hemp plant. It doesn’t contain the psychoactive part of the plant that cannabis contains, known as THC and there are numerous studies currently testing its effectiveness in treating a whole host of ailments, from mild anxiety to epilepsy…

Massachusetts cannabis cafes💜


If you’re at least 21 in Massachusetts, you can legally buy recreational marijuana at more than a dozen stores that have opened over the past several months.

But when it comes to using those products, the law says you can only do so discreetly and privately.

The state’s Cannabis Control Commission voted 3-2 recently to accept the recommendations of a working group that explored the possibility of licensing social-consumption sites for marijuana, a move that potentially would open a new frontier for cannabis businesses and consumers in the Bay State.

The plan calls for a test rollout of such venues in up to a dozen Massachusetts communities. But don’t look for Amsterdam-style cannabis cafes to spring up in the near future. It took more than two years after voters approved a recreational marijuana question for the first retail stores to open, and a full — or even partial — rollout of social-consumption venues could easily take just as long, if it happens at all.


The recommendations narrowly approved by the commission allow for a test of social-consumption sites in 12 volunteer communities, including five that participated in the working group: Amherst, North Adams, Provincetown, Somerville and Springfield. Up to seven others that want to participate will be chosen.

State regulators would be authorized to review applications and grant licenses in those communities for establishments such as cannabis cafes, where people could buy and consume marijuana on the premises. The plan also envisions “event host licenses” for certain one-time gatherings — an outdoor concert, perhaps.

The municipalities would have discretion over the types of licenses and how many can be granted.

Providing opportunities for minority-owned businesses and others that have to date been largely excluded from the legal marijuana industry is listed among the “primary attributes” of the pilot program.

Data collected during the trial period will determine if — and when — social-consumption sites would be allowed elsewhere in Massachusetts.


The working group identified and attempted to address several concerns with social-consumption sites, including the potential for underage pot use, impaired driving and smoking-related health concerns.

Licensees would be required to have plans in place for assuring that no one under 21 enters an on-site consumption area. Employees of the establishments would be required to complete “responsible server” training that includes guidance on cannabis potency and THC absorption times to prevent overserving of patrons.

Establishments also would need to figure out how to determine when a customer is too impaired to drive and have a plan to assist those customers in finding alternative transportation. This part is tricky because there is currently no approved standard for marijuana impairment, and the effects of some products, notably edibles, take considerably longer to show up than others.

Under the working group’s plan, smoking marijuana would not be allowed at cannabis cafes or other indoor establishments, for health and safety reasons. Indoor vaping would be allowed, if the building has adequate ventilation.


Likely not anytime soon.

The commission has invited the public to offer input on the plan, and final regulations would have to be drafted and approved.

The Legislature must also provide at least tacit approval for the plan. Secretary of State William Galvin has determined the state’s current marijuana law doesn’t provide a mechanism for voters in a city or town to weigh in on whether on-site consumption should be allowed in their communities.

Bills to achieve that have been filed in the House and Senate, but no public hearing has been scheduled and it doesn’t appear to be among current priorities for lawmakers.

Republican Gov. Charlie Baker, who would be called upon to sign any such legislation, has been highly skeptical of cannabis cafes but hasn’t ruled them out in the future.


Nearly every U.S. state with legal recreational marijuana has grappled with the question of social use, with differing outcomes.

The working group said it examined rules in other states, including Alaska’s recently approved law that allows pot to be used in designated areas within some stores that sell it.

San Francisco and some other California communities have moved to allow pot lounges, and the Las Vegas City Council approved a plan earlier this month to authorize venues in the city, though not in casinos.

Last year, then-Colorado Gov. John Hickenlooper vetoed a bill to allow marijuana retailers to create so-called tasting rooms.


Fastforward Innovations Limited
EMMAC Life Sciences Ltd

#FFWD is the only

AIM quoted company

with a direct investment in an operational medical cannabis company.

“Our new name, Cryptologic, better represents our business and where we are as an intelligent and experienced miner.

The rebrand couldn’t have come at a better time, as market conditions have improved dramatically from early spring” said John Kennedy FitzGerald, President and Chief Executive Officer of Cryptologic.

“We’ve been in the mining business for over a year and a half and our facilities continue to perform extremely well. Bitcoin is cyclical, and mining is more than just running data centers.

Wayland Negotiates Sale of Canadian Operations to Publicly-Traded Cryptocurrency Miner

The proposed Cryptologic transaction would result in Cryptologic acquiring assets relating to Wayland’s existing Canadian operations in exchange for 57,500,000 common shares of Cryptologic expected to represent approximately 70% of the issued and outstanding Cryptologic common shares following closing and the assumption of liabilities associated with that business.

It is also expected that, following closing, Cryptologic will be led by a management team including Jordan Greenberg as Chief Executive Officer (currently Chief Financial Officer of Cryptologic) and Matthew McLeod as President of Cryptologic.

Mr. Greenberg was the former CFO of Nuuvera Inc., which raised over Cdn$100 million in equity financing then completed several cannabis-related acquisitions, both in Canada and in international markets.

Nuuvera Inc. completed its go-public process through the reverse takeover of a publicly traded shell, then achieved a successful exit through a plan of arrangement with Aphria Inc., valued in excess of Cdn$500 million.

EMMAC acquires 100% of Terra Verde

16 July 2019, London. EMMAC Life Sciences Ltd, the leading European independent medical cannabis and wellness company, is pleased to announce that it has acquired 100% of Terra Verde, LDA (“Terra Verde”), a Portuguese genetics and cultivation company. This acquisition establishes EMMAC as the largest vertically integrated cannabis company in Europe, with operations in eight territories and licensed distribution channels for medical cannabis in Europe’s largest medical cannabis markets, namely Germany, Italy and the UK.

Terra Verde holds oldest cannabis cultivation licence in Portugal, establishes EMMAC as the largest vertically integrated medical cannabis and wellness company in Europe.

The acquisition of Terra Verde is EMMAC’s largest acquisition to date and completes the full integration of EMMAC’s supply chain, which to date comprises GACP cultivation, extraction and manufacturing in accordance with EU Good Manufacturing Practices (GMP), and licensed distribution channels for medical cannabis in the UK, Germany and Italy.

Terra Verde was founded by David Yarkoni, a world-renowned breeder and geneticist who has pioneered plant-based research and production for more than 30 years. In 2014, Terra Verde acquired Portugal’s first, and Europe’s second, active cultivation license. This license allows for eight hectares of greenhouse and outdoors cannabis cultivation. Its current crop of high-grade medical cannabis, which is grown in accordance with EU Good Agricultural and Collection Practices (GACP), is due for harvest in 30 days.

Following completion of the acquisition, EMMAC will begin to invest significantly in Terra Verde’s facilities, including the construction of a GMP-certified facility for storage, processing and manufacturing at the Portuguese site that will serve both the domestic and the international markets.

Antonio Costanzo, CEO of EMMAC, commented: “We are delighted to have acquired Terra Verde, a unique asset in the European medical cannabis space that was founded by one of the most well-regarded plant-based researchers. With the acquisition of Terra Verde, EMMAC is now the largest vertically integrated European cannabis company and a leader in the industry. We are delighted to welcome David and his team in Portugal to EMMAC.

“With this milestone firmly achieved, EMMAC’s focus now is to extend the pan-European reach of our medical and wellness portfolio. We will continue to partner with the best organisations and businesses in the sector and support cutting-edge scientific research to further develop the medical cannabis sector.”

David Yarkoni, Founder of Terra Verde, commented: “Speaking on behalf Terra Verde’s team and shareholders, I am delighted to partner with EMMAC to maximise Terra Verde’s potential to be the best cultivation facility in Europe. We had been approached by multiple organisations, however we decided to partner with EMMAC due to its distribution network, world-class team and scientific approach. EMMAC has built the perfect platform to become the European leader. We look forward to working together.” 

Agreement with Farmalabor gives EMMAC immediate access to Italy, Europe’s second-largest Medical Cannabis Market

9 July 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, is pleased to announce that it has formed a 50/50 joint venture company, Fontana S.R.L. (“Fontana JVCo”), with Sergio Fontana, the founder and major shareholder of Farmalabor S.R.L. (“Farmalabor”), one of Italy’s most active licensed importers and distributors of medical cannabis. Fontana S.R.L. has already submitted applications for licenses to import, store, manufacture and distribute medical cannabis products in Italy, which is the second-largest medical cannabis market in Europe. Pending the grant of such licences, Fontana JVCo will work with Farmalabor as its exclusive partner to commercialise medical cannabis and wellness products as well as commence operations and sales in Italy.

The partnership positions Fontana S.R.L. as Farmalabor’s dedicated cannabis partner. Fontana JVCo combines Farmalabor’s existing medical cannabis sales and operations, pharmacy network and expertise within Italy with EMMAC’s industry expertise and integrated supply chain for cultivation and manufacturing. The partnership agreement with Farmalabor will provide Fontana JVCo with sales services, including distribution to 12,000 pharmacies. It is expected Fontana JVCo has the potential to rapidly establish itself as the largest supplier of medical cannabis and wellness products in Italy.

Antonio Costanzo, CEO of EMMAC, commented: “We are delighted to announce this joint venture with Farmalabor which puts EMMAC in a fantastic position for expansion into the Italian market and extends our licensed medical cannabis and wellness operations beyond the UK, Spain and Germany. We believe that Farmalabor’s extensive experience of the Italian pharmaceutical industry makes it the ideal partner to unlock the full potential of this local market.”

Sergio Fontana, Founder and CEO of Farmalabor, commented: “Speaking on behalf of everyone at Farmalabor, I am delighted to partner with EMMAC on this project. With our extensive knowledge of the medical and pharmaceutical communities combined with EMMAC’s cannabis expertise and range of high-quality medical and wellness products under development, this is the perfect combination to serve Italian patients, doctors and pharmacies with high-quality products.”

EMMAC and Imperial College London manuscript to be published in peer-reviewed Cannabis and Cannabinoid Research Journal

4 July 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, announces that the manuscript, “A comprehensive patient and public involvement programme evaluating perception of cannabis-derived medicinal products in the treatment of acute postoperative pain, nausea and vomiting using a qualitative thematic framework” has been published in ‘Cannabis and Cannabinoid Research’, the only peer-reviewed journal dedicated to the scientific, medical and psychosocial exploration of clinical cannabis, cannabinoids and the endocannabinoid system, and the official journal of the International Cannabinoid Research Society (ICRS).

The manuscript is part of EMMAC’s collaboration with Imperial College London, forged to deliver a long-term comprehensive research programme designed to inform and shape the future of the medical cannabis therapeutic industry. The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

This study represents the first stage of the clinical trial process and was carried out with the Imperial Clinical Trials Unit (ICTU). It represents comprehensive patient and public involvement activities, and prior to peer reviewed publication these data were selected for presentation at the 5th International Emerald Conference in San Diego in February 2019, EMMAC Poster Emerald Conference.

Rokshaw granted General Pharmaceutical Council License to deliver Medical Cannabis direct to Patients across the UK EMMAC

EMMAC Life Sciences Ltd, the European independent medical cannabis company, is pleased to announce its wholly owned subsidiary, Rokshaw Limited (“Rokshaw”), a leading UK EU-GMP certified Specials manufacturer, has successfully obtained its General Pharmaceutical Council (‘GPhC’) pharmacy license.

The GPhC license, in conjunction with its existing licenses, allows Rokshaw to import, manufacture and securely deliver medical cannabis products (‘CBPMs’) direct to UK-based patients. Founded in 2012, Sunderland-based Rokshaw is a leading UK laboratory, manufacturing a wide range of Specials bespoke to patient requirements in an EU-GMP environment that ensures patients across the UK receive the highest-quality products. To date Rokshaw has manufactured more than 6,000 formulations for more than 2,000 pharmacies and hospitals across the United Kingdom.

Get ready for the boom in medical cannabis

Ed McDermott, Executive Director of FastForward Innovations (LON:FFWD), has an unrivalled record of investing in the cannabis sector. His investment boutique was behind the investment in NewEra Pharmacological Products which yielded a stellar return for his investors. FastForward is now behind a number of life sciences companies internationally.

Ed told us that you can evaluate a medical cannabis company in a similar way to evaluating a pharmaceutical company – but that there are additional imponderables, in particular additional legal and regulatory risk. As such, investments in the sector are high risk – but also, potentially, very high return.

In early 2018, I co-founded EMMAC
Life Sciences with a view to becoming
the European independent medical
cannabis champion. In just over a year,
the company has grown to nearly 100
extremely capable individuals and we are
operational in 8 countries and counting.
Despite early warning to the regulators,
FastForward was not approved to
take part in the seed round, which is
disappointing; however, FastForward
now owns 2.6% of EMMAC, which is
similar to its position in Nuuvera.
It is easy to talk about a company I know
and understand very well; it is always
more challenging to objectively look
at opportunities that have no related
parties involved. There are always good
opportunities circulating but whatever
industry you are investing in, I believe
the key things are assets, management
and cash.



involved in a number of presentations, panels and events during

 EMMAC, the European independent medical cannabis company, is pleased to announce an exclusive collaboration with Hyris Ltd, a UK-based biotechnology company

#EMMAC partners with #Hyris to develop a Cannabinoid identification tool #FFWD

EMMAC commences construction of planned EU-GMP facility in Malta

Construction under way in Malta…💚

Billionaire-backed Chinese firm plans Asia’s first e-commerce CBD platform


A company backed by United Kingdom billionaire Jim Mellon and Nuuvera co-founder Lorne Abony plans to establish what they say will be Asia’s first e-commerce platform focusing on CBD-infused products.

The pair are part of a group of investors in Hong Kong-headquartered Regent Pacific that is closing in on a $15 million all-stock takeover of the e-commerce platform Yooya, also based in the city.

Mellon is Regent’s chairman and owns roughly 20% of its shares.

Abony, who founded Canadian cannabis firm Nuuvera before taking it public and selling it to Aphria last year for $425 million, will join the Yooya board on completion of the takeover.

The proposed transaction remains subject to conditions, including completion of due diligence and respective approvals of both companies’ boards.

But Regent CEO Jamie Gibson said he’s hopeful a final deal can be signed in the coming weeks and close shortly thereafter.

Regent plans to start selling CBD through Yooya within 90 days of closing the acquisition. Yooya currently does not sell any CBD products.

Gibson said Yooya would initially market CBD-infused products to overseas Chinese, so long as they live in a jurisdiction where CBD is federally regulated.

Yooya would effectively start as an e-commerce, business-to-business platform connecting overseas Chinese with companies selling CBD products in the jurisdictions where they live.

“Yooya expects to subsequently begin sales in China via cross-border e-commerce (CBEC) channels, including through the CBEC platforms from the PRC’s major e-commerce players – such as TMall and JD – and employing the market’s growing number of free trade zones, and particularly as the PRC regulatory framework for the importation of CBD-based products continues to clarify,” Gibson said.

Abony added: “Within the next 12 months we expect to establish a significant presence in mainland China.”

That would involve Yooya distributing own-branded products and partner brands.

Inside the plan

To fund expansion into new CBD product lines, Regent Pacific is issuing $17.5 million in convertible loan notes.

Gibson said Regent would also look to undertake domestic product sales through a wholly owned foreign entity, pending the acquisition of requisite licenses.

Gibson said the CBD could be sourced in North America, Europe and Australia.

Regent obtained legal analysis on the hemp industry in China from the Dentons law office in Kunming and the Zhong Lun Law Firm in Beijing.

That analysis, shared with Marijuana Business Daily, concluded that cultivating and processing hemp in China is not in conflict with federal law if it is conducted in a province with local hemp regulations and laws. Only the Yunnan and Heilongjiang provinces currently have such regulations.

‘Sleeping giant’

Brent Williams, founder of hedge fund and consulting firm Highwater Financial, said the “sleeping hemp giant” that is Asia is just now starting to wake up.

Williams expects Asian CBD companies to start listing on Asian stock exchanges.

He also does not believe it will be long before those companies have revenues surpassing their North American counterparts.

“The advantage that Yooya has inherently the same as their risk, the early mover advantage could establish early and loyal consumers,” Williams said. “There is no doubt that the Asian CBD market will be the largest in the world and Yooya could help supply consumers with these products.”

Japan is also seeing significant growth in its regulated market for CBD products, according to executives. International companies already tapping that market include Phivida Holdings and Elixinol Global.

Regent shares trade on the Stock Exchange of Hong Kong as 575.

Smearing cannabis on your face: the latest Asian beauty craze

The market for beauty products made from cannabidiol (CBD), a non-psychoactive compound found in cannabis plants, is projected to be worth US$25 billion by 2029

By 2024, the CBD market in China alone would be worth about US$15 billion, said Jamie Gibson, chief executive of Hong Kong-based investment company Regent Pacific Group, which recently signed an agreement to acquire CBD-products e-commerce platform Yooya for US$15 million. They hope to close the acquisition by the third quarter of this year. “There’s no breakdown, but I would say that the [beauty and] wellness sector will be the main driver for this growth,” he said.

Gibson said the plan was for Yooya to become an online retailer for high-end CBD beauty products, including topical creams and skincare lines for domestic consumers in China, as well as overseas shoppers.




announces acquisition of French wellness company.

EMMAC is the 2nd medical cannabis investment made by


we remain the only company on #AIM to be directly invested in

Regent Pacific enters exploding CBD market in Asia through proposed acquisition of Yooya

#Yooya #娱亚互动 💚

FastForward Innovations #FFWD announces an offer has been made for #Yooya FFWDs 15% stake equates to $2.25m

Yooya will expand its sector focus and become the first e-commerce marketing platform to focus on CBD infused products that are designed to awaken the body’s natural healing system and promote better health and sleep; and products that safely eliminate the psychoactive THC from hemp.

Shanghai China🙋

Yooya is a content-driven e-commerce platform that is reshaping the way that brands connect with Chinese consumers.  Total e-commerce revenue in China is forecast to top US$1.8 trillion by 2022. Yooya recognises that the way that Chinese consumers shop and the factors that influence purchase decisions have changed dramatically, with video content consumption being the single most popular activity on the internet in China. Japan, Asia’s second largest e-commerce market in dollar terms, will see nearly 90 million e-commerce shoppers by 2021.

FastForward Innovations Limited Company confirmed that Yooya, its investee company, had adopted the Factom® Harmony™ platform.

Lorne Abony, FastForward’s Chief Executive Officer, was happy to see two of their investee companies forming synergies. He noted that both Factom and Yooya have shown tremendous growth in recent years and believed that the newly formed partnership will bring further growth for all involved parties. Lorne said that his company believes that the Blockchain-as-a-service industry provides the potential of exceptional returns.

Factom Blockchain

The Factom blockchain is a decentralized publication protocol for building record systems that are immutable and independently verifiable. It enables secure storage of digital proofs for data provenance and integrity solutions without disclosing private data or requiring trusted intermediaries.

Unlike other public blockchains, Factom uses a distributed ledger architecture that allows related entries to be linked chronologically in a chain for more efficient storage and retrieval.  Entries can contain any kind of data, but are not intended for storing private data. Entry data is hashed before being written into an entry block, and the actual entry data is stored in distributed hash tables and shared peer-to-peer.

Each directory block is secured in the Factom blockchain is then further secured by cryptographic anchor entries written into Bitcoin. Anchoring into other public blockchains allows for interoperability and third-party security.

The public Factom blockchain is governed by a peer-to-peer network of federated servers whose membership is based on performance and community support. Anyone can read entries and submit write requests for a fixed cost based on chain and entry size.  The Factom protocol is open source and anyone can run a follower node or create a private network for development and production use cases.

EMMAC presents to Scientific Committee (CSST) in Paris

EMMAC Life Sciences Ltd, the European independent medical cannabis company, announces that on Wednesday 15th May, the Company presented to the French Scientific Committee (CSST), regarding EMMAC’s role in advancing scientific research into the medical usage of cannabis for the welfare of patients. The CSST, appointed by the Drug and Safety Agency (ANSM) is working to provide French authorities with recommendations concerning the opening of the French medical cannabis market. Dr Barbara Pacchetti, Chief Scientific Officer at EMMAC, outlined the Company’s vision to bring together cutting-edge scientific research with the latest innovations in cannabis cultivation, extraction and production. EMMAC joined six other companies invited to present to the CSST, including Tilray, Canopy Growth, Aurora Cannabis Inc., and Bedrocan. The full presentation to the CSST can be found here

Antonio Costanzo, CEO of EMMAC, commented: “We are grateful for the opportunity to demonstrate to the CSST how EMMAC is focused on advancing research and development to improve the industry’s understanding of the medical benefits of cannabis. EMMAC believes that the growth of the medical cannabis sector has to be underpinned by the most robust science and is working with leading academic institutions across Europe to advance what we consider to be a huge potential market with significant public health benefits for patients and clinicians.”


committee of French medical experts interviewed representatives from some of the world’s largest cannabis companies today as the country mulls over medicinal cannabis legalization.

The marathon session lasted 4 hours and 48 minutes and it was streamed live on YouTube for anyone interested in developments. Canadian firms Aurora Cannabis, Canopy Growth, and Tilray were joined by U.S. company Columbia Care, Bedrocan of the Netherlands, Clever Leaves of Colombia, and British firm Emmac Life Sciences at the hearing.

The companies’ executives answered a wide range of questions on the medicinal benefits of cannabis, the dosages required, delivery methods, the costs involved and how France might be able to develop a framework for a legal medicinal marijuana trade.

France is one of the only major nations that is yet to legalize medical cannabis use after Germany, the UK, Italy, and the Netherlands all rolled out regulated industries.

The French Ministry of Health is in favour of medicinal marijuana. Towards the end of 2018, the French government authorized this committee of 13 independent healthcare experts to conduct an official study into the benefits of medicinal cannabis.

The health agency will take the recommendations on board, although it has already pledged to start a medicinal cannabis trial this year.

France has the world’s sixth largest economy, behind only the U.S., China, Japan, Germany, and the UK, so it represents a significant potential market for the global cannabis industry.


EMMAC to import cannabis products into Germany supply agreement with CC Pharma

EMMAC Life Sciences Ltd, the European independent medical cannabis company, announces that it has entered the German medical cannabis market through the incorporation of About Nature Health GmbH (“About Nature”), a wholly owned subsidiary of the Company, which will lead the marketing and licensing process for EMMAC in Germany. Working in conjunction with Medalchemy, EMMAC’s fully-licensed GMP certified laboratory and research and development facility in Spain, About Nature has entered into a supply agreement (the “Agreement”) with CC Pharma GmbH (“CC Pharma”), a leading importer and distributor of EU-pharmaceuticals for the German market.

The Agreement allows EMMAC to import high-quality dried cannabis flowers and oils into the rapidly expanding German market, which is the largest medical cannabis market in Europe. According to the Bank of Montreal (1), the German medical cannabis market could potentially produce more than US$5 billion in revenue for global cannabis producers, with an assumption that in seven years, 7.5% of sleep, anxiety and pain prescriptions in Germany will be replaced with medical cannabis.


Antonio Costanzo, CEO of EMMAC, commented: “The decision by CC Pharma to distribute EMMAC medical cannabis product in Germany validates our commitment to delivering the highest quality product and we are delighted to announce the Agreement today. Germany is an important market for EMMAC and we are committed to growing our regional presence, led by general manager, Florian Witt, to ensure that we capitalise on the significant commercial opportunity.

“EMMAC has had a positive start to 2019 and our entry into the German market is the latest significant milestone for the Group. Our tie-up with CC Pharma is a clear demonstration of the significant progress being made at EMMAC and is complementary to the acquisitions completed and key milestones achieved in 2019 in the UK, Malta, Spain and Switzerland. I look forward to updating our stakeholders as we continue to execute on our vision to become the leading European medical cannabis company.”

About CC Pharma GmbH

CC Pharma is a leading importer and distributor of EU-pharmaceuticals for the German market and distributes products to over 13,000 German pharmacies. Founded in 1999, today it has over 230 employees and offices in Germany, Denmark, and the Czech Republic. CC Pharma holds more than 1,800 pharmaceutical licenses and also operates a production, repackaging and labeling facility at its headquarters in Densborn, Germany. During 2018, CC Pharma generated revenue of approximately €262 million, with EBITDA of approximately €10.5 million.

We intend to invest the proceeds, approx £339,500, in the medical cannabis sector. #FFWD


Commenting on the Disposal, CEO Lorne Abony noted, “The partial sale of the Company’s interest in Vemo is the Company’s first exit from an investment in 2019. The Board believes further investments can be realized during the course of 2019 and intends to reinvest the proceeds in the medicinal cannabis sector, furthering FFWDs investment focus on life science, health and technology.”

The science of CBD.

Barbara Pacchetti discussing how EMMAC’s pioneering scientific approach is advancing the cannabis plant as the new medicine of our time

Medcannworldforum (Malta )

The Medical Cannabis World Forum will bring together a unique set of speakers who are shaping the global cannabis industry. From policy makers to business leaders, the forum will provide key insights from the people who are at the forefront of this industry.

The conference will take place on 19th – 21st of November 2019. Medical Cannabis World Forum will be bringing together global industry experts and professionals for a three-day conference on the island of Malta, focused on Legislation, Business, Regulatory, Education & Research.

How big could the cannabis market be in the UK and Europe?




Medical cannabis company EMMAC Life Sciences has acquired Sunderland-based laboratory Rokshaw for an undisclosed sum.

Founded in 2012, Rokshaw produces specials – differently formulated versions of commonly used medications – which is approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). It produces a wide range of specials tailored to patient requirements in an EU GMP environment.

Rokshaw’s licenses, which include Home Office controlled drugs schedule 2 and wholesale dealers authorisation, form part of the deal allowing EMMAC to import medical cannabis into the UK.

Rokshaw is also pursuing additional licenses to enable greater research into the benefits of cannabis-based products for medicinal use as regulations loosen.

Antonio Costanzo, chief executive of EMMAC, said: “We are delighted to announce the acquisition of Rokshaw today.

“This investment not only brings with it an immediate revenue stream but also provides EMMAC instant access to the UK medical cannabis market with the opportunity to grow the existing 45 people-strong team into a centre of medical cannabis excellence for the UK.

“Joining us are the two founders of Rokshaw, Jonathan and Richard Hodgson, who have significant and relevant experience of working in this highly regulated industry as well as a proven track record of delivering high quality product.”

Jonathan and Richard Hodgson, co-founders of Rokshaw, said: “We are really pleased to have joined EMMAC at this exciting stage of its corporate development as we share its vision of becoming the leading European independent medical cannabis company.

“We are confident that the team here at Rokshaw can play an important role in EMMAC achieving its goal through the provision of high-quality product and services to patients across the UK, and by unlocking the potential for the medical cannabis market to meet growing clinician and patient demand.”

Rokshaw is the EMMAC’s second GMP-certified laboratory and will work in conjunction with Medalchemy, its research and development facility in Spain that was recently granted an importation permit by Spanish authorities.

Cannabis firm Emmac Life Sciences to light up in London

A medicinal cannabis start-up is eyeing a London float in what could be the first in a wave of listings amid rapid deregulation.

Emmac Life Sciences is believed to be working with broker Canaccord Genuity on a listing that could value it at £400m. Led by Antonio Costanzo, who previously worked at the Toronto-listed cannabis producer Nuuvera, Emmac was set up last year and aims to become Europe’s leading supplier and producer of the drug.

It is working with Imperial College London to research treatments for pain relief during surgery. Last year it bought a majority stake in drug maker Medalchemy.

UK doctors can now prescribe medicinal cannabis after an outcry over patients being denied a drug that can help control epilepsy.


Medalchemy EMMAC Spanish GMP certified laboratory

EMMAC, the European independent medical cannabis company, is pleased to announce that Medalchemy, EMMAC’s fully-licensed GMP certified laboratory in Alicante, Spain, has secured approval from the Spanish Health Authorities AEMPS to import medical cannabis for scientific research. This landmark announcement places Medalchemy at the forefront of medical cannabis research in Spain, and ensures EMMAC is well positioned to capitalise on anticipated regulatory changes, as demand for premium quality medical cannabis grows in Spain and across Europe.

With over a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs), Medalchemy is an important part of EMMAC’s pan-European research and development initiative to allow the production, registration and exportation of GMP-certified cannabinoid-based APIs.

Antonio Costanzo, CEO of EMMAC, commented: “This is an important milestone for EMMAC, as the Company executes on its strategy to bring specific cannabis regulatory expertise to its expanding asset base, and create a vertically integrated multi-national operation that positions EMMAC at as a trusted leader in the rapidly-growing medical cannabis industry in Europe.”

EMMAC Life Sciences Ltd is the European medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production.

With supply and distribution partnerships throughout Europe, EMMAC is working to establish itself as both a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp and other derivative products.

Cannabis firms head to London for £100bn POT of gold – but is it a good bet or set to go up in smoke?


It’s an industry most of us associate with dingy, smoke-filled bars in Amsterdam and the more liberal states in the US and Canada.

But cannabis companies are making their way to London to tap into a £100billion European market and cash in on the Square Mile’s so-called ‘green rush’ among investors.

In the past few weeks alone, four firms have decided to ditch their previous business plans and instead switch their focus to cannabis-based medicines.

The Mail on Sunday can reveal that Kanabo Research – which is being bought by a shell company listed on London’s main market – has chosen to list in Britain instead of Israel, where it was founded, and is expected to float by summer.

That comes after Highlands Natural Resources, which is listed on the main market, raised £1.3million to launch a cannabis operation in Colorado. It said the new venture, called Zoetic Organics, would grow hemp and sell products such as organic hemp oil.

It will join Sativa Investments, which became the first London-listed cannabis investment vehicle when it floated a year ago. Since then, its share price has more than doubled to value the company at £38million.

The fourth firm to switch focus is Block Commodities, run by the cousin of Tory party deputy chairman James Cleverly. 

As revealed last month, Chris Cleverly has turned the focus of his agriculture business to cannabis. Block, also listed on the NEX, is buying a firm with licences to grow the crop on 4,000 acres of farmland in Sierra Leone.

Another company that has been active in recent months is FastForward Innovations, which is listed on London’s junior market AIM and is chaired by Jim Mellon, a friend of Nigel Farage and a Brexit donor.

It has just invested in EMMAC Life Sciences, a London-based medical cannabis company, in its second cannabis investment in 18 months, having previously focused on backing high-tech companies.

Another company eyeing a possible listing on AIM is Jacana, a medicinal cannabis firm founded by internet entrepreneur Alexandra Chong.

The businesswoman – who went to boarding school in England and previously ran a dating app – has a 100-acre farm in Jamaica, where she was born, and plans to sell medicinal cannabis to patients in North America, Europe and the UK.

Chong, whose lavish wedding to Sir Richard Branson’s nephew Jack Brockway was attended by Princess Eugenie and Kate Winslet, has raised £15million from angel investors including London venture capital star Eileen Burbidge.

The flurry of activity will only increase as other firms pile into the European market, experts believe. Until now, the US, Canada, and Israel have led the way in cannabis floats because they were the first to relax rules on the drug’s use.

But cannabis firms are convinced the City of London’s deep-pocketed investors and bankers are ready to plough into the market, which is estimated could be worth a staggering €115.7billion (£100million) by 2028 in Europe alone, according to consultancy Prohibition Partners.

Many of the companies choosing London have been spurred on by the changes to the NHS after the rules on marijuana-based treatments were relaxed last year.

Patients can now get a prescription through the NHS for medicines based on cannabidiol, better known as CBD, but only to treat epilepsy or nausea caused by chemotherapy and only if other treatments have not worked.

But with so many companies rushing to tap London’s funds, fears are rising of a ‘Wild West’ culture that could leave private investors vulnerable to being exploited amid the hype due to the lack of regulation.

There are many companies that have no assets – the only asset they have is a licence to cultivate cannabis. They haven’t constructed greenhouses or production facilities yet and they’re getting very high values.

He said: ‘In stock markets, you always have this wave of up and down. And for sure, prices will not go up forever. Having said that, it’s an industry that has real value, that generates nice sales already, and it’s an industry that’s seeing regulation moving forward.’

One City stockbroker said the regulators were being careful about which cannabis companies to allow to list in fear of damaging the reputation of the whole sector.

‘If something lists on Aim that’s cannabis and it goes straight to a £1billion market cap and then blows up, then the whole of London looks terrible,’ the broker warned. 

One factor is that cannabis is still illegal in the US despite some states decriminalising its use for medicine and recreational use.

Still, this has not stopped the marijuana industry from flourishing in North America, especially after Canada became the second country in the world, after Uruguay, to legalise recreational cannabis use. 

That has led to a wave of ‘pot stocks’ flotations in North America and a string of deals, such as Marlboro maker Atria Group paying $1.8billion for a 45 per cent stake in Canadian cannabinoid firm Cronos Group.

In London, there remains scepticism about ‘potmania’, which has seen entrepreneurs such as Alexandra Chong raise £15million to launch her medicinal cannabis firm, Jacana. Khalaf said: ‘Investors need to look at these cannabis companies with a fine tooth comb – they should take a good look under the bonnet.



Why are people eating CBD and will it get me high?

Cannabidiol, or as it’s better known CBD, is a legal cannabinoid (chemicals found in cannabis) and can be sold in the UK.

It’s not the psychoactive cannabinoid that gets you high, called THC. Instead it’s a product believed by its high-street users to have medicinal properties, such as relaxation and pain-, nausea- and anxiety-relief, although studies are not conclusive.

So why are we increasingly seeing CBD-labelled coffees, cakes and croissants in shops, cafes and restaurants all over the UK?

What is it doing in food?

CBD is normally sold in combination with a base oil, such as olive or coconut, as a supplement, vape, gel to be applied to the skin and more recently, in food and drink.

“Businesses have picked up on growing public awareness and have been promoting their products online, in high-street retailers and increasingly in food and drink,” says Professor in Substance Use, Harry Sumnall, Liverpool John Moores University. We spoke to chefs at two restaurants who use CBD on their menus in completely different ways.

“CBD is actually hard to cook with. It has a disgusting taste”, says Greg Hanger, head chef at Kalifornia Kitchen in London, who has created an entire CBD afternoon tea. Greg pays attention to the type of oil that the CBD is mixed with, saying “coconut oil CBD is great in Thai cooking balanced with coriander, ginger and lime. Olive oil CBD is great for Middle Eastern foods like hummus or you could even mask the flavour with rosemary and put it in cheesy sauce or mashed potatoes.”

“CBD tends to work well in foods with a stronger, earthy taste, such as chocolate and coffee”, says Meg Greenacre, head chef at Erpingham House in Norwich. “I’ve been inspired by menus in London to create a delicious CBD brownie for our customers here. I was surprised that during taste tests, no one could tell which brownie the CBD was in and actually, most people thought it was the batch that did not contain it. I am looking into adding CBD to more sweet bakes such as nutty flapjacks and beetroot chocolate cake, which naturally have a deeper and richer flavour, complementing the earthy, almost bitter, taste and smell of CBD oil.

“When you cook with CBD, you have to be careful not to heat the mixture at too high a temperature”, advises Meg. A search on CBD websites brings up details of CBD evaporating and losing its ‘health’ properties past 160–180C, though “there is also little understanding of what happens to CBD when you cook it or add it to a drink”, says Professor Sumnall

Is CBD a miracle cure?

“There is a greater public awareness of the potential therapeutic uses of medical cannabis and cannabinoids such as CBD, particularly in light of the UK government decision to permit some cannabis prescriptions in response to high-profile campaigns by the families of children affected by severe epilepsy,” says Professor Sumnall.

“The emerging UK CBD industry, inspired by the successes of the legal cannabis industry in the USA, has adopted a similar marketing strategy, and whilst the Medicines and Healthcare Regulatory Agency rules mean products can’t make direct health claims without going through formal licensing, the language of ‘wellbeing’ allows them to bypass regulation.

“But there is no good scientific evidence that these consumer products have any real benefits.

“Many of the CBD products available on the high street contain so little CBD that you would need to consume vast quantities to even approach some of the doses that are administered in clinical trials of medicines”, concludes Sumnall.

Coffees and cakes may contain between 5–10mg of CBD. But clinical trials administer doses of around 100–1,500mg per day, with medical supervison.

However, it is not clear whether it would be advisable to consume higher doses of CBD than is currently in these products. “I do worry that if people believe a small amount is good and it’s completely safe, they may believe a large amount is better, says Dr Sarah Jarvis, GP and Clinical Director of Patient Info.”

“The problem we have is there hasn’t been enough research and we just don’t know”, Jarvis continues.

This is currently not a regulated market in the UK and so there are no rules on the quality, source, or content of CBD in these type of products, said Professor Sumnall. Michael Wight, Head of Food Safety Policy for The Food Standards Agency said, “We are not aware of any significant safety concerns related to CBD, but as part of the ‘novel foods’ authorisation process they do need to be evaluated for safety. We are continuing to actively monitor food safety aspects of CBD. If we find credible evidence to say that CBD extracts in general, or specific products containing CBD, risk harm to the public, they will be removed from sale.”

Is CBD safe?

According to a report from the World Health Organization, CBD doesn’t exhibit the effects indicative of substance abuse or dependency in humans, like THC can, and has a relatively low toxicity. “To date, there is no evidence of public health-related problems associated with the use of pure CBD”, it says.

“Many cannabis-based products are available to buy online, but their quality and content is not known. They may be illegal and potentially dangerous,” says the NHS. If you choose to buy CBD in any form, it is best to choose a reputable company.

#cbdcakes @cbdcakes cbd cakes uk

Cafe says brownies mixed with cannabis plant extract are a hit with customers

It is a treat you might expect to find in one of Amsterdam’s infamous coffee shops, rather than inside a Norwich cafe.

But brownies mixed with a cannabis plant extract are now being sold at That Cafe on St Augustines Street – and they are proving popular with customers.

The chocolate brownies were added to the cafe’s menu following the introduction of hot drinks infused with cannabidiol (CBD) earlier this year.

CBD is a non-psychoactive chemical compound found in cannabis plants which some believe can help with a range of conditions from anxiety to multiple sclerosis (MS).

Following the popularity of the infused hot drinks, the family-run cafe has now added it to its homemade brownies

Barista Sarah White said: “It hasn’t got the psychoactive element of the plant, so you won’t get high off it.

“It just helps relax your muscles, whereas other people use it to help with anxiety.

“You would be surprised how many elderly people come in and ask for it.”

Ms White said the brownies contain 24mg of CBD oil and are mixed with vegan chocolate. Once baked, the oil cannot be tasted.

While almost all cannabinoids are controlled substances under the Misuse of Drugs Act, CBD is not and can be sold in the UK.

Other items on the menu containing the oil include coffees and hot chocolates.

While it is tasteless in the brownies, tea made from CBD oil has an earthy taste.

“It is brilliant for relaxing”, Ms White said. “And we have had no negative feedback.

“We do get the odd person come in and say ‘are you the stoner cafe?’ and I have to say ‘I think you’ve come to the wrong place’.”

A World Health Organization report published in summer 2018 concluded cannabidiol is “generally well tolerated with a good safety profile”.

The report found there was no public health-related problems associated with the use of pure CBD.

Some believe it can help with various medical conditions, but there are no conclusive scientific studies on this.

Cafe owner Chris Featherby said he introduced the CBD infused hot drinks as his mother has MS and found it helped with her condition.


A coffee shop in Glastonbury is offering customers a different kind of morning buzz on top of their usual caffeine kick.

Customers at Coffee Zero on High Street, can now upgrade their beverage to a CBD-infused hot drink for an extra £1.50.

CBD, short for cannabidiol, is a non-psychoactive cannabis plant extract which some believe can help conditions ranging from anxiety and depression to arthritis and heart disease.

John Lintern, the owner of Coffee Zero, introduced the drink to the menu on Wednesday, April 12.

They plan to expand the range if it is successful, there could even be ice cream!

CBD can be consumed in many ways one of which is through food.

Today, many cannabis edibles are available from biscuits, and cakes to teas, and gummies.

Compared to other intake methods, cannabis edibles can be easier and better.

The relief provided lasts for longer

it takes CBD edibles minimum half-hour and maximum one hour to deliver results.

However, the effects of cannabis eatables last longer than other delivery modes.

Since CBD in treats is combined with other food items, it takes its time to release in the bloodstream.

This is because food is slowly digested. Compared to inhaling weed, the effects of edibles can last for two to four additional hours.

There’s also no need to worry about overdosing in this case as you are aware of the amount of CBD added to each serving. In fact, you can also find a range of CBD treats to buy from market shelves.

It has lower psychoactive effects

There’s no risk of lung irritation